by Marisa Wexler, MS | Mar 2, 2026 | Myeloma News
Early results from the Phase 2/3 MIRACLE clinical trial suggest that the experimental chemotherapy drug annamycin may offer meaningful benefit as a second-line treatment for people with relapsed or refractory acute myeloid leukemia (AML), an aggressive and often...
by Marisa Wexler, MS | Feb 27, 2026 | Myeloma News
A new blood test powered by artificial intelligence (AI) could offer a life-saving head start for patients at high risk of pancreatic cancer. Clearnote Health has officially launched its enhanced Avantect Pancreatic Cancer Test, a diagnostic tool designed to catch one...
by Marisa Wexler, MS | Feb 26, 2026 | Myeloma News
An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food and Drug Administration (FDA). The experimental treatment, known as SRN-101, is being developed for recurrent high-grade glioma, an...
by MM360 Staff | Feb 26, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Feb 25, 2026 | Myeloma News
People in the U.S. with certain gynecological cancers that are resistant to first-line chemotherapies now have a new treatment option: The U.S. Food and Drug Administration (FDA) has approved the use of the immune-modulating therapies Keytruda (pembrolizumab) and...
by MM360 Staff | Feb 25, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
